Anti-Müllerian Hormone in Breast Cancer Clinical Practice

This study aims to evaluate serum anti-Müllerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls. The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.

Inclusion Criteria: * Women aged 20-55 years. * Patients with a diagnosis of breast cancer at any of the specified stages of treatment or follow-up, or healthy female volunteers. * Blood sampling as part of routine clinical care (breast cancer patients) or willingness to undergo a single blood draw (healthy volunteers). Exclusion Criteria: * Inability or unwillingness to participate in the study.